title: Chemotherapy during pregnancy: what is really safe?
authors.affiliation: Division of Hematology/Oncology, European Institute of Oncology, Milan, Italy.
authors.forename: Fedro
authors.initials: F
authors.lastname: Peccatori
authors.forename: Giovanni
authors.initials: G
authors.lastname: Martinelli
authors.forename: Oreste
authors.initials: O
authors.lastname: Gentilini
authors.forename: Aron
authors.initials: A
authors.lastname: Goldhirsch
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D015251:Epirubicin / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005315:Fetal Diseases / Q000139:chemically induced*; D006801:Humans; D015255:Idarubicin / Q000009:adverse effects / Q000627:therapeutic use; D018811:Maternal Exposure / Q000009:adverse effects; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy*; D011256:Pregnancy Outcome; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D015251:Epirubicin; D004317:Doxorubicin; D015255:Idarubicin